Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...

Edwards Lifesciences Inc. says it will appeal a Delaware judge’s decision not to bar the manufacture and sale of Medtronic Inc.’s CoreValve aortic valve replacement. Medtronic Inc. (NYSE:MDT) managed ...

The potential is high for TAVR adoption in emerging markets, according to Venkat Rajan, an analyst at Frost & Sullivan. “It is, however, coming in at a higher price point than traditional valves,” he ...

In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

The first day at the recently concluded Transcatheter Cardiovascular Therapies (TCT) meeting in Washington, D.C., was reportedly heavily focused on TAVR - transcatheter aortic valve replacement ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

TCT 122: Perioperative and In-Hospital Outcomes of Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the National Inpatient Sample 2016-2021 Receive the ...

ATLANTA -- For transcatheter aortic valve replacement (TAVR) candidates with a small aortic annulus, the two leading platforms offered differing hemodynamic valve performances despite being similarly ...

Atlanta — A randomized transcatheter aortic valve replacement (TAVR) trial demonstrated that a self-expanding device performs better on multiple prognostically important measures of valve function at ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...